MGMT and glioblastoma: Previously, we have demonstrated that pharmacological inhibition of gap junctions via INI-0602, a novel experimental gap junction inhibitor, increased the susceptibility of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylated glioblastoma cells to standard chemotherapeutic agent temozolomide (TMZ) [4].